Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
PALI Palisade Bio
- 0.6698
- -0.0110-1.62%
Close Apr 1 16:00 ET
- 0.6797
- +0.0099+1.48%
Post 17:55 ET
2.94MMarket Cap-0.07P/E (TTM)
0.6808High0.6401Low54.65KVolume0.6500Open0.6808Pre Close36.47KTurnover1.34%Turnover RatioLossP/E (Static)4.40MShares9.650052wk High0.39P/B2.74MFloat Cap0.638852wk Low--Dividend TTM4.09MShs Float594000.0000Historical High--Div YieldTTM5.98%Amplitude0.6388Historical Low0.6670Avg Price1Lot Size
Palisade Bio Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 250K | 0 | 0 | 0 | 250K |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --250K | --0 | --0 | --0 | --250K |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 13.47%14.86M | 15.47%3.38M | -4.90%3.59M | 16.68%4.21M | 32.17%3.67M | -14.47%13.1M | -23.88%2.93M | -5.62%3.78M | 1.04%3.61M | -28.52%2.78M |
| Selling and administrative expenses | -6.55%5.8M | -16.69%1.3M | -13.02%1.46M | 10.54%1.58M | -5.14%1.46M | -29.23%6.2M | 3.52%1.56M | -19.33%1.67M | -36.50%1.43M | -47.49%1.54M |
| -General and administrative expense | -6.55%5.8M | -16.69%1.3M | -13.02%1.46M | 10.54%1.58M | -5.14%1.46M | -29.23%6.2M | 3.52%1.56M | -19.33%1.67M | -36.50%1.43M | -47.49%1.54M |
| Research and development costs | 31.48%9.06M | 52.01%2.08M | 1.57%2.14M | 20.72%2.63M | 78.40%2.21M | 5.28%6.89M | -41.49%1.37M | 9.13%2.1M | 65.30%2.18M | 29.41%1.24M |
| Operating profit | -15.68%-14.86M | -15.47%-3.38M | 4.90%-3.59M | -16.68%-4.21M | -45.24%-3.67M | 16.11%-12.85M | 23.88%-2.93M | 5.62%-3.78M | -1.04%-3.61M | 34.95%-2.53M |
| Net non-operating interest income expense | 20.00%-12K | 25.00%-3K | 25.00%-6K | 33.33%-2K | -1K | -15.38%-15K | -33.33%-4K | -100.00%-8K | 40.00%-3K | 0 |
| Non-operating interest expense | -20.00%12K | -25.00%3K | -25.00%6K | -33.33%2K | --1K | 15.38%15K | 33.33%4K | 100.00%8K | -40.00%3K | --0 |
| Other net income (expense) | -22.68%433K | 207.89%41K | -41.05%112K | -39.27%133K | -22.22%147K | -47.37%560K | -129.01%-38K | 1,087.50%190K | -82.24%219K | 159.81%189K |
| Special income (charges) | --0 | ---- | ---- | ---- | ---- | 45.12%-225K | ---- | ---- | ---- | ---- |
| -Less：Restructuring and merger&acquisition | --0 | ---- | ---- | ---- | ---- | -45.12%225K | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | -44.84%433K | -78.07%41K | -41.05%112K | -39.27%133K | -22.22%147K | -69.62%785K | 42.75%187K | -55.40%190K | -82.24%219K | -76.20%189K |
| Income before tax | -17.38%-14.44M | -12.55%-3.34M | 3.03%-3.49M | -20.25%-4.08M | -50.73%-3.53M | 13.74%-12.3M | 20.13%-2.97M | 9.90%-3.6M | -44.75%-3.39M | 44.35%-2.34M |
| Income tax | ||||||||||
| Net income | -17.38%-14.44M | -12.55%-3.34M | 3.03%-3.49M | -20.25%-4.08M | -50.73%-3.53M | 13.74%-12.3M | 20.13%-2.97M | 9.90%-3.6M | -44.75%-3.39M | 44.35%-2.34M |
| Net income continuous Operations | -17.38%-14.44M | -12.55%-3.34M | 3.03%-3.49M | -20.25%-4.08M | -50.73%-3.53M | 13.74%-12.3M | 20.13%-2.97M | 9.90%-3.6M | -44.75%-3.39M | 44.35%-2.34M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -17.38%-14.44M | -12.55%-3.34M | 3.03%-3.49M | -20.25%-4.08M | -50.73%-3.53M | 13.74%-12.3M | 20.13%-2.97M | 9.90%-3.6M | -44.75%-3.39M | 44.35%-2.34M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | 0 | 0 | -94.44%16K | 0 | 16K | ||||
| Net income attributable to common stockholders | -17.23%-14.44M | -12.55%-3.34M | 3.46%-3.49M | -20.25%-4.08M | -50.73%-3.53M | 15.34%-12.32M | 25.87%-2.97M | 9.50%-3.61M | -44.75%-3.39M | 44.35%-2.34M |
| Basic earnings per share | 62.27%-10.19 | 70.12%-1.1264 | 68.56%-2.32 | 58.13%-3.32 | 43.54%-4.59 | 89.11%-27.01 | 62.72%-3.77 | 88.00%-7.38 | 90.84%-7.93 | 95.82%-8.13 |
| Diluted earnings per share | 62.27%-10.19 | 70.12%-1.1264 | 68.56%-2.32 | 58.13%-3.32 | 43.54%-4.59 | 89.11%-27.01 | 62.72%-3.77 | 88.00%-7.38 | 90.84%-7.93 | 95.82%-8.13 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now